Understanding how well lupus patients follow their hydroxychloroquine treatment
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus in a Hospital Internal Medicine Consultation
This study is trying to see how well people with lupus take their hydroxychloroquine medication and what might make it harder for them to stick to their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06161363 on ClinicalTrials.gov |
What this trial studies
This observational project examines the compliance of patients with systemic lupus erythematosus in taking hydroxychloroquine, commonly known as Plaquenil. Using the Morisky Medication Adherence Scale 8 (MMAS 8), the study aims to identify specific factors that contribute to non-compliance among these patients. By correlating questionnaire results with hydroxychloroquinemia levels, the researchers hope to develop tools for early detection of non-compliance in general medical practices. The findings could lead to improved management strategies for lupus patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with systemic lupus erythematosus who have been on hydroxychloroquine for more than six months.
Not a fit: Patients who are not currently taking hydroxychloroquine or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance adherence to treatment in lupus patients, leading to better health outcomes.
How similar studies have performed: While there have been studies on medication adherence in chronic illnesses, this specific approach using the MMAS 8 in lupus patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age \>18 years * Patient with systemic lupus erythematosus * Treatment with PLAQUENIL for \> 6 months with dosage of hydroxychloroquinemia planned during the consultation.
Where this trial is running
Toulouse
- Toulouse Hospital — Toulouse, France (Recruiting)
Study contacts
- Study coordinator: Laurent Sailler, MD
- Email: sailler.l@chu-toulouse.fr
- Phone: 0561779654
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.